The Effect of Pneumoperitoneum (Raised Pressure in the Peritoneal Cavity) During Robotic Kidney/Prostate Cancer Surgery.

June 18, 2023 updated by: Hayder Alhusseinawi, Aalborg University Hospital

The Effect of Pneumoperitoneum During Robot Assisted Laparoscopic Renal/ Prostatic Cancer Surgery - a Randomized Clinical Study Investigating Patient and Surgeon Outcome.

Within all the surgical specialties, major surgeries are performed whenever possible, as minimally invasive procedures to reduce blood loss, reduce pain and discomfort after surgery, avoid major scars, provide a faster recovery and thus shorter hospital stay. Such minimally invasive procedures in urinary tract surgeries are often performed as laparoscopic or robotic surgeries where CO2 (carbon dioxide) is insufflated into the abdominal cavity to create a working space for the surgeon's instruments. That high pressure created in the abdominal cavity (pneumoperitoneum) to create a workspace for the surgeon start a series of physiological changes in the heart, lung and kidney.

Today, most laparoscopic, and robotic operations are performed with pneumoperitoneum of approximately 12-15 mm Hg, despite the fact that international guidelines recommend the use of the lowest intra-abdominal pressure (IAP) possible allowing adequate exposure of the operative field rather than using a routine pressure level.

Investigator will conduct a randomized double-blind study involving 120 patients (2 groups of 60). The first group will be operated with standard pressure in the abdominal cavity 12-15 mm Hg (high IAP), patients in the second group will be operated on with a reduced pressure of ≈ 7 mmHg (low IAP).

Investigator would like to assess the practical feasibility of operating under low IAP. Quality of recovery of patients in relation to both physical and mental status, and post-operative use of pain killer will be also investigated using a validated questionnaire . Finally, Invistigator will examine the impact of IAP on post-operative renal function, and risk of kidney injury.

Hypothesis is carrying out laparoscopic/robotic surgeries under low IAP can optimize the post-operative quality of recovery, decrease pain and use of pain killer, improve post-operative renal function, and decrease risk for kidney injury. On the other hand low IAP can risk overview for surgeon, make workspace smaller and raise risk of bleeding.

Study Overview

Detailed Description

A total of 120 patients between the ages of 18 and 80 years who were scheduled for elective robotic radical nephrectomy/ prostatectomy will included in the study. This is randomized controlled double-blind clinical trial.

A standard anesthesia protocol will be used in both groups. Bladder catheter inserted by the OP-nurse. After ports installment under IAP of 7 mm Hg, the surgeon leaves the operation field and sits at a surgical console. The ground nurse opens the sealed letter which indicated the pressure for operation (electronic randomization was previously performed by investigator using https://www.graphpad.com/quickcalcs/index.cfm) The required IAP sets by the ground nurse before the surgery started. Assistants are not blinded in the study, but the surgeon is. Intra-abdominal pressure will be maintained at 7 mmHg in Group Low IAP and at 12 mmHg in Group High IAP throughout the surgery. If under operation the surgeon required to raise the IAP because of bad views, or bleeding, he/she can always ask the ground nurse to raise the pressure by 2- or 3-mm Hg at a time until surgeon obtain the preferred view. This involved both groups. Patient will not be excluded from study if pressure increased, but the duration of raised IAP will be registered.

During the operation, the surgical working space will be evaluated by surgeon using an adopted version of SRS (Surgical rating scale). 1st time during mobilization of bowel, 2nd time during renal vascular dissection, and last time when surgeon remove the kidney and set it in the Endobag.

All patients asked to register their 24-hour urine production before the operation day. Intra-operative urine output will be also registered. 10 ml urine will be collected 3 times in order to investigate the risk of Acute Kidney Injury (AKI) by kidney injury biomarker (u-NGAL, og KIM-1). Pre-operatively during urinary catheter placement, 2-hour post-operatively, and 24 hours after operation. Urine samples collected and stored in -80 C for later analyses.

Investigator will test the quality of recovery using a validated Quality of recovery-15 (QoR-15) questionnaire before the surgery and at day 1,3,14,30 post-op.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Jutland
      • Aalborg, North Jutland, Denmark, 9000
        • Aalborg University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients diagnosed with kidney/prostate cancer at the department of Urology, Aalborg University Hospital, who are offered radical nephrectomy/prostatectomy.
  • Speaks and understands Danish

Exclusion Criteria:

  • Patient diagnosed with kidney cancer but can be treated with partial nephrectomy.
  • Patients with severe to end stage chronic kidney disease (CKD stage 4-5)
  • Inability to understand or comply with instructions.

Withdrawal Criteria:

  • Inability to complete the surgery without raising the pneumoperitoneum for low pneumoperitoneum arm.
  • Complications that require re-operation which can change the quality of recovery of primary operation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low Intra-abdominal pressure
Intra-abdominal pressure will be set at 7 mm Hg during the procedure.
7 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery
Active Comparator: High (standard) intra-abdominal pressure
Intra-abdominal pressure will be set at 12 mm Hg during the procedure.
12 mm Hg pneumoperitoneum during robot-assisted laparoscopic surgery

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of recovery
Time Frame: fulled by the patient pre-operatively and then on post-operative day 1,3,14 and 30
Changes in Quality of recovery assessed by QoR-15 Questionaire from pre-operative to day 30 post-operative level. Participiants fill in quistionaire pre-operatively, day 1,3,14,30
fulled by the patient pre-operatively and then on post-operative day 1,3,14 and 30
Surgical rating scale
Time Frame: intra-operative
assessed 3 times during surgery. 1st during mobilization of bowel, then during renal vessels dissection, and last time during removing and insertion of kidney in the endobag.
intra-operative
Risk Of Acute kidney injury (AKI)
Time Frame: 24 hours after surgery
post-operative renal function and risk for AKI evaluated by u-NGAL
24 hours after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
post-operative use of painkillers
Time Frame: 24 hours after surgery
All post-operative painkiller registered and converted to morphine using Morphine Milligram Equivalent (MME)
24 hours after surgery
Intra-operative urine output
Time Frame: intra-operative
intra-operative
Duration of operation in minutes
Time Frame: intra-operative
intra-operative
Intra-operative bleeding in ml
Time Frame: intra-operative
intra-operative
u- KIM-1 level
Time Frame: Before surgery
Kidney injury molecule in urine
Before surgery
u-NGAL
Time Frame: 24 hours after surgery
Neutrophil gelatinase-associated lipocalin in urine
24 hours after surgery
u- KIM-1 level
Time Frame: 24 hours after surgery
Kidney injury molecule in urine
24 hours after surgery
S.creatinine, and eGFR
Time Frame: 24 hours after surgery
Kidney injury marker
24 hours after surgery
S.creatinine and eGFR
Time Frame: 10 days after surgery
Kidney injury marker
10 days after surgery
S.creatinine and eGFR
Time Frame: 21 days after surgery
Kidney injury marker
21 days after surgery
Other Kidney injury markers, include; TFF,VEGF, Osteoactivin, Clusterin, and Calbindin
Time Frame: Before surgery
Kindey injury markers
Before surgery
Other Kidney injury markers, include; TFF,VEGF, Osteoactivin, Clusterin, and Calbindin
Time Frame: 24 hours after surgery
Kidney injury markers
24 hours after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Hayder Al-husseinawi, M.D., Aalborg University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 23, 2020

Primary Completion (Actual)

February 28, 2022

Study Completion (Actual)

February 28, 2022

Study Registration Dates

First Submitted

February 6, 2021

First Submitted That Met QC Criteria

February 15, 2021

First Posted (Actual)

February 16, 2021

Study Record Updates

Last Update Posted (Actual)

June 22, 2023

Last Update Submitted That Met QC Criteria

June 18, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumoperitoneum

Clinical Trials on Low intra-abdominal pressure

3
Subscribe